Back to journals
Academic JournalOpen Access

European Journal of Psychotraumatology

6 Papers Indexed in Blossom

Data updated

Research Footprint

European Journal of Psychotraumatology has 6 tracked papers indexed in Blossom (2020–2025) from 33 authors, most often covering MDMA and Ketamine, across PTSD, Depressive Disorders and Substance Use Disorders (SUD).

Published Papers

Open Accessindividual

Self-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder

This secondary analysis (n=82) of a Phase III RCT of MDMA-assisted therapy found significant improvements in both uncompassionate self-responding and compassionate self-responding across all six Self-Compassion Scale subscales, most with large effect sizes. Changes in self-compassion fully mediated the reductions in PTSD severity and depressive symptoms observed with MDMA-AT versus placebo plus therapy, though no significant effects were seen for alcohol or substance use outcomes.

Published
Journal
European Journal of Psychotraumatology
Authors
Agin-Liebes, G. I., Zeifman, R. J., Mitchell, J.
Open Accessindividual

Expert opinions on implementation of MDMA-assisted therapy in Europe: critical appraisal towards training, clinical practice, and regulation

This survey (n=68) of researchers and clinicians involved in MDMA-assisted therapy (MDMA-AT) examines opinions on clinical practices, training, and regulation. The study finds broad support for training standardization and highlights challenges in the national (European) approval process. Experts emphasize the importance of science-informed policy, active regulatory involvement, and international cooperation to integrate MDMA-AT into the European mental healthcare system, particularly for treating PTSD.

Published
Journal
European Journal of Psychotraumatology
Authors
Van Dongen, N. N. N., Zijlmans, J., Vermetten, E., Herpers, J., Maximets, N.
Open Accessmeta

So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs

This systematic review & meta-analysis (2024; s=6; n=221) of randomised control trials (RCTs) on ketamine interventions for PTSD finds a small advantage for ketamine over control conditions in reducing PTSD symptoms at 24 hours post-initial infusion, but bias and heterogeneity pose concerns, indicating that blind penetration and the placebo effect might contribute to reported therapeutic effects.

Published
Journal
European Journal of Psychotraumatology
Authors
Borgogna, N. C., Owen, T., Vaughn, J., Johnson, D. A. L., Aita, S. L., Hill, B. D., Clave, P.
Open Accessindividual

Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder

This analysis of a clinical trial (n=22) examines the role of therapeutic alliance in MDMA-assisted psychotherapy (MDMA-AP) for treating chronic PTSD. It reports that after controlling for baseline PTSD severity, a strong therapeutic alliance at the mid and late stages of treatment (sessions 4 and 9) significantly predicts lower clinician-assessed and self-reported PTSD severity post-treatment.

Published
Journal
European Journal of Psychotraumatology
Authors
Zeifman, R. J., Kettner, H., Ross, S., Weiss, B., Mithoefer, M. C., Mithoefer, A. T., Wagner, A. C.
Open Accessindividual

Self-reported PTSD is associated with increased use of MDMA in adolescents with substance use disorders

This survey study (n=121) explored the co-occurrence of PTSD in patients with a substance use disorder (SUD). It was found that SUD patients with PTSD were more likely to use MDMA than those without PTSD and MDMA use was associated with avoidance symptoms. The authors conclude that MDMA use might reflect an attempt to self-medicate to deal with avoidance symptoms however, it may also be the case that MDMA use led to more severe avoidance symptoms.

Published
Journal
European Journal of Psychotraumatology
Authors
Basedow, L. A., Kuitunen-Paul, S., Wiedmann, M. F., Roessner, V., Golub, Y.
Open Accessindividual

MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial

This open-label study (n=12, 6 couples) describes the safety, tolerability, and efficacy of MDMA in combination with cognitive-behavioral conjoint therapy (CBCT) where one half of the couple was battling with PTSD.

Published
Journal
European Journal of Psychotraumatology
Authors
Monson, C. M., Wagner, A. C., Mithoefer, A. T., Liebman, R. E., Feduccia, A. A., Jerome, L., Yazar-Klosinski, B., Emerson, A., Doblin, R., Mithoefer, M. C.

Quick Facts

Papers Indexed
6
h-Index
77
Open Access
Yes
Publisher
Taylor & Francis
Country
United Kingdom
Website
Visit